Phentermine vs Qsymia: What Actually Separates the Two
One is an old short-term appetite suppressant, the other a combination pill built for long-term weight management, and that gap changes everything.
Maybe a clinic handed you phentermine, you lost a little, then hit a wall a few weeks in. Or you saw the name Qsymia, noticed phentermine listed right there in the ingredients, and wondered whether the two are really the same thing. They are related, but they are not interchangeable, and the distance between them is wider than the shared ingredient makes it look. One is a decades-old appetite suppressant meant for a short stretch of weeks. The other is a combination pill designed to be taken for the long haul. What follows is a plain, side-by-side look, written to help you have a sharper conversation with a clinician rather than to push you toward either one.
The difference in one sentence
Phentermine on its own is a short-term jump-start. Qsymia is phentermine plus a second medicine, topiramate, formulated for ongoing use. That single design choice ripples through everything that matters: how long you can stay on it, how much weight people lose on average, and what has to be watched while you do.
What each one is actually approved to do
Phentermine is a sympathomimetic amine anorectic, which is a technical way of saying it is a stimulant that suppresses appetite. It has been around a long time; its initial U.S. approval dates to 1959, and it is a Schedule IV controlled substance. Its label indicates it only as a short-term add-on, a few weeks, alongside diet, exercise, and behavior change for obesity, in adults with a BMI of 30 or higher, or 27 or higher with a risk factor such as controlled high blood pressure, diabetes, or high cholesterol. The label is blunt about the ceiling: tolerance to the appetite-suppressing effect usually develops within a few weeks, and the drug should be stopped if that happens. It was never built for chronic use.
Ready to start?
$199 Skeptics' Trial, see if it works for you
One month of medical-grade compounded semaglutide, the $119 doctor review, and a free B-12/lipotropic injection. No long-term commitment.
Start the 30-day trialQsymia is a fixed-dose combination of phentermine and topiramate extended-release, FDA-approved in July 2012 for chronic, long-term weight management in adults with the same BMI thresholds. In June 2022 the FDA extended it to adolescents aged 12 and older with obesity. It is titrated in steps, starting low and increasing only under the prescriber's direction, and the label builds in checkpoints: if a patient has not lost at least 5 percent of body weight after set intervals, the guidance is to reassess rather than continue on faith. That "keep going only if it is working" logic is part of the design.
What the weight-loss numbers show
Qsymia has the clearer trial record for weight. In the pivotal 56-week EQUIP and CONQUER studies, patients on the recommended dose lost roughly 7 to 8 percent of body weight, and those on the top dose about 11 percent, versus roughly 1 to 2 percent on placebo. Phentermine by itself does not have comparable long-term trials, precisely because it is not a long-term drug; its evidence is short-term, and its effect tends to fade as tolerance sets in. Worth stating plainly: there is no head-to-head randomized trial pitting phentermine alone against Qsymia at their marketed doses. Any ranking between them is a comparison of separate studies, not a single fair race. And averages hide a wide spread. Some people respond well, some barely move, and the only way to learn your own response is a supervised trial.
The topiramate side: pregnancy and the brain
The biggest reason Qsymia asks more of you is topiramate. It is teratogenic. First-trimester exposure raises the risk of oral clefts, meaning cleft lip or palate, with epidemiologic studies showing roughly a two- to fivefold increase. Because of that, Qsymia is not to be used in pregnancy and is dispensed through a restricted FDA program, the Qsymia REMS, using certified pharmacies. Anyone who could become pregnant is advised to have a negative pregnancy test before starting and monthly during treatment, along with reliable contraception throughout. That is a safety guardrail, not a formality.
Topiramate also brings warnings that plain phentermine does not. They include trouble with attention, memory, or finding words; tingling in the fingers and toes, called paresthesia; a metabolic acidosis that may need monitoring; changes in mood and sleep; and a rare but urgent risk of sudden vision changes from acute myopia or angle-closure glaucoma. Resting heart rate can rise as well. None of this means the medicine is unsafe, but it is why Qsymia is a monitored drug rather than a set-and-forget one, and why the topiramate component should never be stopped abruptly.
The phentermine side: heart rate and blood pressure
Both drugs contain phentermine, so both share its cardiovascular caution, and Qsymia inherits it. As a stimulant, phentermine can raise heart rate and blood pressure. It is contraindicated in cardiovascular disease such as coronary artery disease, arrhythmias, heart failure, and stroke, and in uncontrolled high blood pressure, hyperthyroidism, glaucoma, agitated states, a history of drug misuse, and use of an MAOI now or within the past 14 days. There are rare associations with primary pulmonary hypertension and valvular heart disease. This is why a prescriber checks blood pressure, heart rhythm, and your history before writing for either pill, and keeps an eye on them while you take it. It is also why "just get me some phentermine" is not the casual request people sometimes assume it is.
Where both sit next to the GLP-1 medicines
Phentermine works through a stimulant pathway, and Qsymia adds topiramate's sense of fullness on top of it. The newer GLP-1 and dual-incretin medicines work through a different route entirely, the gut-hormone satiety pathways, and they too are meant for long-term use. On average they produce larger weight loss. In their trials, semaglutide 2.4 mg (Wegovy) reached about 15 percent of body weight at 68 weeks, and tirzepatide (Zepbound) about 15 to 21 percent at 72 weeks. Two cautions about that comparison. First, those figures come from separate studies, not a head-to-head against Qsymia, so treat the gap as a general pattern rather than a precise verdict. Second, a bigger average does not automatically make a medicine right for you; eligibility, other conditions, cost, and how you tolerate it all weigh in. If you want to go deeper, our comparisons of semaglutide versus phentermine and semaglutide versus Qsymia lay out the mechanics, and who qualifies for a GLP-1 covers who is a candidate in the first place.
Wegovy is a registered trademark of Novo Nordisk A/S, and Zepbound is a registered trademark of Eli Lilly and Company; this clinic is not affiliated with or endorsed by either.
How to choose, and where we fit
Here is the honest summary. Phentermine alone is a low-cost, short-term appetite suppressant, a few weeks of a jump-start, not a long-term plan. Qsymia keeps the phentermine but adds topiramate so that ongoing weight management becomes possible, at the cost of more monitoring, above all strict pregnancy prevention. Neither is a casual choice, and neither should start before a clinician reviews your blood pressure, heart history, mood, medications, and pregnancy plans. If a stimulant is a concern for you, there is a different oral combination worth reading about in our Contrave versus Qsymia comparison. And do not stop, start, or change any prescription on your own; that is a decision to make with the person who prescribes it.
For transparency, we do not dispense phentermine or Qsymia. Our program uses physician-supervised compounded semaglutide and tirzepatide, prepared by licensed U.S. pharmacies, which are not FDA-approved, not brand-identical, and whose results vary by individual, after a one-time medical review. If you are trying to sort out where these pills stand next to the injectables, Dr. Anjmun Sharma, MD can walk through which cautions apply to your history and what a safe plan would actually involve. That conversation, not a headline, is where the right answer lives.
Frequently asked questions
Is Qsymia the same as phentermine?
Not quite. Qsymia contains phentermine, but it pairs it with a second medicine, topiramate extended-release, in one capsule. That combination is what makes Qsymia FDA-approved for long-term weight management, while phentermine on its own is labeled only for short-term use of a few weeks. So they share an ingredient but are not interchangeable, and they differ in approved duration, average results, and what has to be monitored.
Can you take phentermine long term for weight loss?
Phentermine's own label indicates it only as a short-term add-on, a few weeks, to diet, exercise, and behavior change. The label also notes that tolerance to its appetite-suppressing effect usually develops within a few weeks, at which point it should be stopped. If you need an option built for ongoing use, that is a different conversation, and one to have with a prescriber rather than by refilling on your own.
Which causes more weight loss, phentermine or Qsymia?
Qsymia has the stronger trial record for weight. In its 56-week EQUIP and CONQUER studies, average loss was roughly 7 to 8 percent on the recommended dose and about 11 percent on the top dose, versus roughly 1 to 2 percent on placebo. Phentermine alone does not have comparable long-term trials, and there is no head-to-head study comparing the two at their marketed doses, so treat any ranking as a comparison of separate studies. Individual results vary widely either way.
Why does Qsymia require a pregnancy test every month?
Because Qsymia contains topiramate, which is teratogenic and has been linked to oral clefts such as cleft lip or palate when taken in the first trimester, with a roughly two- to fivefold increase in risk. To reduce that risk, Qsymia is dispensed through a restricted program, the Qsymia REMS, and anyone who could become pregnant is advised to have a negative pregnancy test before starting and monthly during treatment, plus reliable contraception. It is a genuine safety guardrail, not paperwork.
Is phentermine or Qsymia better than semaglutide?
On average, GLP-1 medicines produce larger weight loss than either phentermine or Qsymia. In their trials, semaglutide 2.4 mg reached about 15 percent of body weight and tirzepatide about 15 to 21 percent, while Qsymia averaged roughly 7 to 11 percent depending on dose. Those numbers come from separate studies, not head-to-head trials, and they work through different mechanisms. Bigger average loss does not automatically make one right for you; a clinician weighs your health history, other conditions, cost, and tolerance.
This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.